Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Dong-won | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Na, Seong Kyun | - |
dc.contributor.author | Kim, Seung Young | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Hyun, Jong Jin | - |
dc.contributor.author | Jung, Sung Woo | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Koo, Ja Seol | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Lee, Sang Woo | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.contributor.author | Um, Soon Ho | - |
dc.date.accessioned | 2021-09-01T13:58:08Z | - |
dc.date.available | 2021-09-01T13:58:08Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-06 | - |
dc.identifier.issn | 1478-3223 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/64841 | - |
dc.description.abstract | Aim & Background Advanced hepatocellular carcinoma (HCC) (Barcelona clinic liver cancer [BCLC] stage C) needs subclassification to more accurately predict survival. This study aims to establish a substaging system of BCLC stage C HCC patients for accurate prognosis. Methods Data from 564 patients with newly diagnosed BCLC stage C HCC from three tertiary-care hospitals affiliated with the Korea University (training set) were assessed retrospectively. Variables affecting overall survival (OS) were analysed, and patients were substaged according to the number of prognostic factors they fulfilled. The substaging system was validated using a nationwide database from the Korean Liver Cancer Association (validation set; n = 742). Results In the training set, tumour factors such as tumour burden >= 10 cm, major portal vein invasion and distant metastasis, as well as underlying liver function, were independently associated with OS. BCLC stage C was classified into four substages (C1-4) according to the number of prognostic factors. Substages C1, C2, C3 and C4 showed a median OS of 17.50 months (95% confidence interval [CI], 8.57-26.43), 10.13 months (95% CI, 8.17-12.09), 4.20 months (95% CI, 3.42-4.98), and 2.90 months (95% CI, 2.34-3.46) respectively (P < 0.05). This substaging system also had good discriminative ability in predicting survival in the validation set. In addition, it was considered that the BCLC substaging is better than Hong Kong liver cancer substaging in predicting the OS for patients with advanced HCC. Conclusion Our substaging for BCLC stage C might help predict patients' prognosis better. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | HEPATIC RESECTION | - |
dc.subject | TUMOR SIZE | - |
dc.subject | SURVIVAL | - |
dc.subject | SORAFENIB | - |
dc.subject | CLASSIFICATION | - |
dc.subject | METASTASIS | - |
dc.subject | EXPERIENCE | - |
dc.subject | SELECTION | - |
dc.subject | IMPACT | - |
dc.title | Prognostic assessment using a new substaging system for Barcelona clinic liver cancer stage C hepatocellular carcinoma: A nationwide study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim, Hyung Joon | - |
dc.contributor.affiliatedAuthor | Seo, Yeon Seok | - |
dc.contributor.affiliatedAuthor | Kim, Seung Young | - |
dc.contributor.affiliatedAuthor | Hyun, Jong Jin | - |
dc.contributor.affiliatedAuthor | Jung, Sung Woo | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seol | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Lee, Sang Woo | - |
dc.contributor.affiliatedAuthor | Um, Soon Ho | - |
dc.identifier.doi | 10.1111/liv.14117 | - |
dc.identifier.scopusid | 2-s2.0-85065490770 | - |
dc.identifier.wosid | 000469049400015 | - |
dc.identifier.bibliographicCitation | LIVER INTERNATIONAL, v.39, no.6, pp.1109 - 1119 | - |
dc.relation.isPartOf | LIVER INTERNATIONAL | - |
dc.citation.title | LIVER INTERNATIONAL | - |
dc.citation.volume | 39 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1109 | - |
dc.citation.endPage | 1119 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | HEPATIC RESECTION | - |
dc.subject.keywordPlus | TUMOR SIZE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | METASTASIS | - |
dc.subject.keywordPlus | EXPERIENCE | - |
dc.subject.keywordPlus | SELECTION | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordAuthor | hepatocellular carcinoma | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordAuthor | stage | - |
dc.subject.keywordAuthor | substaging | - |
dc.subject.keywordAuthor | treatment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.